Philip Morris loses two EU nicotine pouch patents to BAT appeals
The EPO revoked Philip Morris pouch patents EP 3773494 and EP 3809884 after the company withdrew approval of the patent texts in appeals brought by BAT entities, leaving divisional filings as the remaining question.
Key points
- The EPO revoked Philip Morris patent EP 3773494 on 13 October 2026, publishing the decision on 17 November after a Nicoventures Trading appeal.
- Patent EP 3809884 was revoked on 24 September 2026 in a challenge brought by British-American Tobacco (Investments) Limited.
- Both revocations followed Philip Morris withdrawing approval of the patent texts, so the EPO made no final finding on novelty or inventive step.
- Both patents share a 7 June 2019 priority date and require at least 15% water in the pouch composition.
- EP 4108105 B1 was granted on 4 June 2025 and EP 4079290 remains a divisional application in the related chains.
On this page
- Revocations rest on procedure, not on findings about the technology
- Both patents claim a 15% water threshold and a 2019 priority date
- Divisional filings decide how much protection remains
- PMI and BAT carry the dispute across ZYN and VELO
- Suppliers face patent clearance on formulation details
- Questions readers ask
Philip Morris Products S.A. lost European patent EP 3773494 when the EPO Board of Appeal revoked it on 13 October 2026, a decision published on 17 November, after the company withdrew its approval of the patent text during a Nicoventures Trading appeal.
It was the second such revocation in under a month. A different BAT entity, British-American Tobacco (Investments) Limited, had already seen EP 3809884 revoked on 24 September 2026, published 30 September.
Neither outcome turned on whether the inventions were new or inventive. Under Article 113(2) of the European Patent Convention the EPO may decide on a patent only in a text the proprietor submits or agrees to, so the withdrawal left nothing to uphold.
Revocations rest on procedure, not on findings about the technology
The EPO did not reach a final substantive determination on patentability in either case, according to the two decisions. The Board of Appeal set aside the earlier Opposition Division decision and revoked.
EP 3773494 had been maintained in amended form by the Opposition Division in December 2024, which Nicoventures then appealed. The company initially sought dismissal of that appeal before withdrawing approval of the text at oral proceedings.
Public materials reviewed for the reports do not explain Philip Morris’s commercial reasons for the withdrawals. Law360 reported that neither company’s representatives responded immediately to requests for comment.
Both patents claim a 15% water threshold and a 2019 priority date
The two filings share a Danish priority application dated 7 June 2019 and name the same inventors, though they came from different European and PCT applications with distinct claims.
| Item | EP 3809884 | EP 3773494 |
|---|---|---|
| Appeal number | T 0057/25 | T 0263/25 |
| Technology | Nicotine distribution through pouch membrane | Free-base nicotine, resin and moisture |
| Key quantitative claim limits | At least 15% of total nicotine in membrane; at least 15% water in composition | Nicotine-to-resin weight ratio 0.1–2.0; at least 15% water |
| Opponent | British-American Tobacco (Investments) Limited | Nicoventures Trading Limited |
| Decision date | 24 September 2026 | 13 October 2026 |
| Publication date | 30 September 2026 | 17 November 2026 |
| Outcome | Revoked | Revoked |
EP 3773494 covers a composition mixing free-base nicotine with ion-exchange resin at a weight ratio between 0.1 and 2.0, plus at least 15% water by weight. The specification discusses polacrilex resin, plant-based fibers, sugar alcohols and pH-regulating ingredients.
EP 3809884 requires at least one water-insoluble fiber, at least 15% water and nicotine inside the pouch, with the membrane carrying additional nicotine equal to at least 15% of the product total. Its specification describes nicotine in the membrane releasing during the initial period of use.
Divisional filings decide how much protection remains
Separate applications in the same chains have their own examination, claims and legal status. EP 4108105 B1, a divisional from the EP 3809884 chain, was granted on 4 June 2025; EP 4552511 sits in the same record.
EP 4079290 is a divisional application tied to EP 3773494, with published claims on nicotine pouch compositions. The scope of any surviving protection depends on the enforceable claims of those filings, not on the revoked parents.
Some public patent databases still list EP 3809884 and EP 3773494 as active. The published revocation decisions are the authoritative record.
PMI and BAT carry the dispute across ZYN and VELO
Philip Morris Products S.A. was the proprietor in both cases; the challengers were two different BAT entities. PMI acquired ZYN through its 2022 purchase of Swedish Match, while BAT competes with VELO in the United States, Europe and other markets.
Both groups hold portfolios covering pouch formulations, materials, manufacturing processes and nicotine-release technology. The decisions did not establish whether the claimed technologies appear in any commercial ZYN or VELO product, and neither found infringement.
Suppliers face patent clearance on formulation details
For manufacturers and exporters, the revoked claims no longer block work on free-base nicotine and resin ratios or on membrane nicotine loading, subject to whatever the divisional filings still cover. VapeBrief’s analysis: pouch developers selling into Europe should check EP 4079290, EP 4108105 and EP 4552511 before finalising formulations, and treat database status flags as unreliable until updated. BAT’s use of separate entities in the two oppositions shows the challenges were coordinated across its portfolio rather than isolated.
The next signal is the status and claims of the divisional applications, particularly EP 4079290, which has not yet been shown as granted in the records cited.
Questions readers ask
Why did the EPO revoke the Philip Morris pouch patents?
In both appeals Philip Morris withdrew its approval of the patent text. Under Article 113(2) of the European Patent Convention the EPO can decide only on a text the proprietor submits or agrees to, so the Board of Appeal revoked each patent without a final ruling on novelty or inventive step.
Do the revoked patents affect ZYN or VELO products?
The published decisions did not establish whether the claimed technologies are used in specific ZYN or VELO products, and neither found that any marketed product infringed the patents.
Sources
18+ only. This site is for adult readers and provides news and information only. It is not medical, legal or purchase advice. Nicotine is addictive. Always check the official text of any regulation in your market. Health Information



